167 related articles for article (PubMed ID: 34207763)
21. Incorporating radiomic feature of pretreatment 18F-FDG PET improves survival stratification in patients with EGFR-mutated lung adenocarcinoma.
Chen YH; Wang TF; Chu SC; Lin CB; Wang LY; Lue KH; Liu SH; Chan SC
PLoS One; 2020; 15(12):e0244502. PubMed ID: 33370365
[TBL] [Abstract][Full Text] [Related]
22. [Prognostic value of pretreatment (18)F-FDG PET-CT metabolic parameters in patients with advanced extranodal NK/T cell lymphoma].
Wu LL; Liang JH; Wang L; Xu W; Ding CY
Zhonghua Zhong Liu Za Zhi; 2019 Nov; 41(11):831-836. PubMed ID: 31770850
[No Abstract] [Full Text] [Related]
23. Prognostic Value of the Volumetric Parameters of Dual-Time-Point
Okazaki E; Seura H; Hasegawa Y; Okamura T; Fukuda H
AJR Am J Roentgenol; 2019 Dec; 213(6):1366-1373. PubMed ID: 31509426
[No Abstract] [Full Text] [Related]
24. Prognostic significance of semi-quantitative FDG-PET parameters in stage I non-small cell lung cancer treated with carbon-ion radiotherapy.
Shrestha S; Higuchi T; Shirai K; Tokue A; Shrestha S; Saitoh JI; Hirasawa H; Ohno T; Nakano T; Tsushima Y
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1220-1227. PubMed ID: 31758225
[TBL] [Abstract][Full Text] [Related]
25. Prognostic Value of Metabolic and Volumetric Parameters of Preoperative FDG-PET/CT in Patients With Resectable Pancreatic Cancer.
Im HJ; Oo S; Jung W; Jang JY; Kim SW; Cheon GJ; Kang KW; Chung JK; Kim EE; Lee DS
Medicine (Baltimore); 2016 May; 95(19):e3686. PubMed ID: 27175707
[TBL] [Abstract][Full Text] [Related]
26.
Polverari G; Ceci F; Bertaglia V; Reale ML; Rampado O; Gallio E; Passera R; Liberini V; Scapoli P; Arena V; Racca M; Veltri A; Novello S; Deandreis D
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32380754
[TBL] [Abstract][Full Text] [Related]
27. Risk stratification in patients with advanced-stage breast cancer by pretreatment [(18) F]FDG PET/CT.
Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC
Cancer; 2015 Nov; 121(22):3965-74. PubMed ID: 26249241
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of the quantitative metabolic volumetric measurement on 18F-FDG PET/CT in Stage IV nonsurgical small-cell lung cancer.
Liao S; Penney BC; Zhang H; Suzuki K; Pu Y
Acad Radiol; 2012 Jan; 19(1):69-77. PubMed ID: 22142679
[TBL] [Abstract][Full Text] [Related]
29. Texture analysis of
Nakajo M; Jinguji M; Nakabeppu Y; Nakajo M; Higashi R; Fukukura Y; Sasaki K; Uchikado Y; Natsugoe S; Yoshiura T
Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):206-214. PubMed ID: 27613542
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of total lesion glycolysis in patients with advanced non-small cell lung cancer receiving chemotherapy.
Zaizen Y; Azuma K; Kurata S; Sadashima E; Hattori S; Sasada T; Imamura Y; Kaida H; Kawahara A; Kinoshita T; Ishibashi M; Hoshino T
Eur J Radiol; 2012 Dec; 81(12):4179-84. PubMed ID: 22884163
[TBL] [Abstract][Full Text] [Related]
31. Nodal parameters of FDG PET/CT performed during radiotherapy for locally advanced mucosal primary head and neck squamous cell carcinoma can predict treatment outcomes: SUVmean and response rate are useful imaging biomarkers.
Lin P; Min M; Lee M; Holloway L; Forstner D; Bray V; Fowler A
Eur J Nucl Med Mol Imaging; 2017 May; 44(5):801-811. PubMed ID: 28004135
[TBL] [Abstract][Full Text] [Related]
32. Metabolic tumor burden on baseline
Chen S; He K; Feng F; Wang S; Yin Y; Fu H; Wang H
Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1830-1839. PubMed ID: 31187163
[TBL] [Abstract][Full Text] [Related]
33. Validation of Metabolically Active Tumor Volume and Total Lesion Glycolysis as 18F-FDG PET/CT–derived Prognostic Biomarkers in Chemorefractory Metastatic Colorectal Cancer.
Woff E; Hendlisz A; Ameye L; Garcia C; Kamoun T; Guiot T; Paesmans M; Flamen P
J Nucl Med; 2019 Feb; 60(2):178-184. PubMed ID: 29959212
[TBL] [Abstract][Full Text] [Related]
34. Pretreatment quantitative
Gencturk M; Ozturk K; Koksel Y; Li F; Cayci Z
Clin Imaging; 2019; 53():17-24. PubMed ID: 30308429
[TBL] [Abstract][Full Text] [Related]
35. Clinical utility of 18F-FDG PET parameters in patients with advanced nasopharyngeal carcinoma: predictive role for different survival endpoints and impact on prognostic stratification.
Chan SC; Chang JT; Lin CY; Ng SH; Wang HM; Liao CT; Chang CJ; Lin SY; Yen TC
Nucl Med Commun; 2011 Nov; 32(11):989-96. PubMed ID: 21862944
[TBL] [Abstract][Full Text] [Related]
36. Prognostic impact of incomplete surgical clearance of radioiodine sensitive local lymph node metastases diagnosed by post-operative (124)I-NaI-PET/CT in patients with papillary thyroid cancer.
Sabet A; Binse I; Grafe H; Ezziddin S; Görges R; Poeppel TD; Bockisch A; Rosenbaum-Krumme SJ
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1988-94. PubMed ID: 27118127
[TBL] [Abstract][Full Text] [Related]
37. 18F-FDG PET/CT metabolic tumor volume and total lesion glycolysis predict outcome in oropharyngeal squamous cell carcinoma.
Lim R; Eaton A; Lee NY; Setton J; Ohri N; Rao S; Wong R; Fury M; Schöder H
J Nucl Med; 2012 Oct; 53(10):1506-13. PubMed ID: 22895812
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of 18F-FDG PET /CT metabolic parameters in patients with locally advanced pancreatic Cancer treated with stereotactic body radiation therapy.
Ren S; Zhu X; Zhang A; Li D; Zuo C; Zhang H
Cancer Imaging; 2020 Mar; 20(1):22. PubMed ID: 32156306
[TBL] [Abstract][Full Text] [Related]
39. Predictive value of (18)F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study.
Caobelli F; Alongi P; Evangelista L; Picchio M; Saladini G; Rensi M; Geatti O; Castello A; Laghai I; Popescu CE; Dolci C; Crivellaro C; Seghezzi S; Kirienko M; De Biasi V; Cocciolillo F; Quartuccio N;
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):404-13. PubMed ID: 26381775
[TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of metabolic tumor volume and total lesion glycolysis in patients with advanced cervical carcinoma.
Calles-Sastre L; Mucientes-Rasilla J; San-Frutos Llorente LM; Royuela A; Garcia-Espantaleón Navas M; Herrero Gámiz S; Pérez-Medina T
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(1):17-21. PubMed ID: 30366731
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]